This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

(Circulation. 2004;110:643.)
© 2004 American Heart Association, Inc.

Issue Highlights

An extract of the first 250 words of the full text is provided, because this article has no abstract.

OUTCOMES IN CHILDREN WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION, by Yung et al.

Long-term survival of children with idiopathic pulmonary arterial hypertension is poor without treatment. Yung et al report significantly improved outcomes in 77 children diagnosed between 1982 and 1995 and treated through 2002 with calcium channel blockade and/or epoprostenol. Ten-year survival was 81% in acute responders to vasodilator testing; 61% in all patients treated with epoprotstenol; and 78% in all children treated in the recent medical era. Acute responders to vasodilator testing should be treated with calcium channel blockers as first-line therapy. Patients who are nonresponders to vasodilator testing at diagnosis are considered for more aggressive therapy, such as epoprostenol. The decrease in survival and treatment success after 5 years in all children with idiopathic pulmonary arterial hypertension supports the role for transplant evaluation before treatment failure. See p 660.

CELIPROLOL, A VASODILATORY ß-BLOCKER, INHIBITS PRESSURE OVERLOAD–INDUCED CARDIAC HYPERTROPHY AND PREVENTS THE TRANSITION TO HEART FAILURE VIA NITRIC OXIDE–DEPENDENT MECHANISMS IN MICE, by Liao et al.

ß-Adrenergic receptor blockers exert beneficial effects in patients with heart failure. Although it is clear that the fundamental mechanism of this benefit is blockade of the ß-adrenergic receptor, additional properties of various ß-blockers may contribute to their overall effects. Celiprolol is a ß-1–selective blocker that also upregulates and/or activates the nitric oxide signaling system. In this issue, Liao et al provide evidence that enhancement of nitric oxide signaling by celiprolol may ameliorate many aspects of the pathological myocardial remodeling that occurs in response to pressure overload. Although the relative contributions that ß-adrenergic receptor blockade and nitric oxide enhancement contribute to the actions of celiprolol remain to be determined, this article suggests that enhancement of nitric oxide signaling could have therapeutic . . . [Full Text of this Article]

Related Articles:

Celiprolol, A Vasodilatory ß-Blocker, Inhibits Pressure Overload–Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide–Dependent Mechanisms in Mice

Yulin Liao, Masanori Asakura, Seiji Takashima, Akiko Ogai, Yoshihiro Asano, Yasunori Shintani, Tetsuo Minamino, Hiroshi Asanuma, Shoji Sanada, Jiyoong Kim, Soichiro Kitamura, Hitonobu Tomoike, Masatsugu Hori, and Masafumi Kitakaze
Circulation 2004 110: 692-699. [Abstract] [Full Text]

Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000

Elizabeth Selvin and Thomas P. Erlinger
Circulation 2004 110: 738-743. [Abstract] [Full Text]

Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension

Delphine Yung, Allison C. Widlitz, Erika Berman Rosenzweig, Diane Kerstein, Greg Maislin, and Robyn J. Barst
Circulation 2004 110: 660-665. [Abstract] [Full Text]

Coronary Sinus Tachycardia Driving Atrial Fibrillation

Martin Rotter, Prashanthan Sanders, Yoshihide Takahashi, Li-Fern Hsu, Frederic Sacher, Mélèze Hocini, Pierre Jaïs, and Michel Haïssaguerre
Circulation 2004 110: e59-e60. [Extract] [Full Text]